Sponsored by:
Facebook (FB)
JP Morgan (JPM)
AutoZone (AZO)
Yahoo (YHOO)
Focus Stocks
Featured Stories
Medtronic Reports Fourth Quarter Earnings
Cracker Barrel Reports Earnings, Increases Guidance
Best ETFs For Facebook Exposure
Is Yum! Brands Closing in to Support?
Intuitive Surgical Bullish Signs
Abbott Labs Bulls in Charge
Published on Friday, 30 December 2011 12:34 Written by Christopher Lynn
New York, December 30th (TradersHuddle.com) - Shares of Abbott Laboratories (NYSE:ABT) booked a new 52 week high today by trading above $56.39, traders are definitely monitoring Abbott Labs' price action to see if this move attracts further buying into the stock.
Abbott Laboratories (NYSE:ABT) develops, manufactures, and sells a broad and diversified line of health care products and services. The Company's products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors. The company was founded in 1888 and is based in Abbott Park, Illinois.
Abbott Labs is currently trading 0.06% versus its previous trading session close, and it has calculated support and resistance at $48.96 and $54.88 respectively. Clearly with this action this range has been penetrated, and traders will be reviewing price action to establish a new tradable range
The overall market index S&P 500 is trading lower by -0.16% from its previous trading close, which means that Abbott Labs stock is outperforming the overall market.
Related Articles
- Abbott Launches PediaSure SideKicks® Clear for Picky Eaters
- Abbott's New FreeStyle InsuLinx Blood Glucose Monitoring System with Insulin Calculator Now Available in Canada
- Abbott's New FreeStyle InsuLinx Blood Glucose Monitoring System with Insulin Calculator Now Available in Canada
- Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
- Abbott Reaches Settlement Agreement on Depakote
- Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury
- Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
- Abbott to Present at Deutsche Bank 37th Annual Health Care Conference
- New Products from Abbott's EAS® Sports Nutrition Brand Help Athletes Improve Post-Workout Recovery and Meet Fitness Goals
- Abbott and St. Jude Medical Broaden Alliance for Cardiovascular Products in the United States
Related Partner Headlines
- Abbott Laboratories (ABT): Today's Featured Health Care Winner - TheStreet.com
- Abbott Helps Big Pharma Look Even Worse - TheStreet.com
- Abbott Laboratories (ABT): Today's Featured Health Care Loser - TheStreet.com
- Abbott Reaches Settlement Agreement on Depakote; Will Pay Total of $1.6B - Benzinga
- 10 Best-Performing 'Dividend Aristocrats' - TheStreet.com
- Abbott to Acquire Action Pharma's Investigational Compound, AP214 for $110M - Benzinga
- Abbott Stock Hits New 52-Week High (ABT) - TheStreet.com
- Pfizer Nears Deals for Nutrition, Animal Health Units: Report - TheStreet.com
- More Hep C Drug Abstracts Leak Ahead of EASL Confab - TheStreet.com
- Abbott Stock To Go Ex-dividend Tomorrow (ABT) - TheStreet.com
Volatile market? That's when profit potential skyrockets for options traders. Now you can get up to 50 trade opportunities a week from top options experts -- plus much more -- on our exciting new site OptionsProfits.
Try it FREE!
TradersHuddle Search
| Sponsored By:
|
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
Stock Market
Loading
